Melancholic MDD: different presentation and treatment but same response

Even if melancholic features represent more severe depression, clinicians seem to have developed augmentation and combination strategies to treat this common subtype of disease. 

Important insights into the melancholic subtype of major depression (as characterized by DSM criteria1) are revealed by a new pan-European study conducted by the long-established European Group for the Study of Resistant Depression and reported at CINP 2021 Virtual by Lucie Bartova (Medical University of Vienna, Austria). 

The cross-sectional survey of 1410 patients, with retrospective assessment of treatment response, shows that melancholic depression is2:

  • found in 60.7% of patients with major depressive disorder (MDD)
  • associated with a significantly greater likelihood of unemployment
  • more severe than non-melancholic MDD and more likely to lead to inpatient treatment, and
  • associated with psychotic features and suicide risk.

Treatment outcome was similar for melancholic and non-melancholic patients

 

Adjunctive treatment used in 73%

People with melancholic depression were more likely than those with non-melancholic features to have received a treatment where antidepressant were used in augmentation/combination strategies (39% vs 14%). Thirty-three percent had had an adjunctive antipsychotic, compared with only 14% of non-melancholic patients2.

The difference in use of adjunctive medication in melancholic patients was greatest for benzodiazepines (40% vs 22%) and least for mood stabilizers (13% vs 9%)2.

Dr Bartova was inclined to view the greater use of augmentation or combination strategies in melancholic patients as related to their more severe condition. If so, the strategy seems to work since outcomes in melancholic and non-melancholic patients were very similar2.

Outcomes in melancholic and non-melancholic patients were very similar2

 

Response rates almost identical

Response was judged to have occurred in 25% of the melancholic subtype and 24% of non-melancholic patients.  Around 40% of both groups were regarded as treatment resistant2.

Melancholic features represent a subtype of MDD characterized by features such as  anhedonia and emotional blunting, agitation or retardation, guilt, early waking and weight gain, 1 and the subtype is commonly thought of as biologically determined. But much remained to be known about its prevalence in real world populations and its responsiveness to therapy.

Previous studies3-5 had suggested that melancholic MDD, when compared with non-melancholic patients, is less likely to respond to SSRIs, more likely to respond to ECT, and less likely to respond to psychotherapy. Treatment response in general is faster, and the placebo response in clinical trials is relatively low.

 

DSM: Diagnostic and Statistical Manual of Mental Disorders
CINP: The International College of Neuropsychopharmacology 
MDD: Major depressive disorder
SSRI : Selective Serotonin Reuptake Inhibitor
ECT: Electroconvulsive therapy

 

BE-NOTPR-0110, approval date 02/2022

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References

1. APA 2013 Diagnostic and Statistical Manual of Mental Disorders

2. Dold M, et al. Prog Neuropsychopharmacol Biol Psychiatry, 2021;110:110285

3. Rush AJ. Clin Psychiatry 2007; 68 Suppl 8:4-10

4. Musil R et al. Int J Methods Psychiatric Research 2018; Mar;27(1):e1569

5. Lin CH et al.  Psychiatry Res 2016; 238:368-373

You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intended for health care professionals.
All the information included in this Website is directed to healthcare professionals. If you are a HCP please proceed to the registration page.
Congress
Register for access to Progress in Mind in your country